Investment Research
Investment research requires rigorous fundamental analysis, accounting forensics, competitive moat assessment, and valuation modeling. Analyzing public equities, corporate filings, or private venture opportunities demands deconstructing SEC filings (10-K, 10-Q), evaluating management capital allocation track records, and modeling investment returns with explicit margin-of-safety parameters.
1. SEC Filing Deconstruction & Forensic Accounting
Inspect audited financial statements for earnings quality:
- Form 10-K (Annual) & Form 10-Q (Quarterly):
- Item 1 (Business): Moat analysis, customer concentration risks, supplier dependencies.
- Item 7 (Management's Discussion & Analysis - MD&A): Organic growth vs acquisition growth, pricing power, headwinds.
- Item 8 (Financial Statements & Notes): Revenue recognition policies, off-balance-sheet commitments, stock-based compensation (SBC), pending litigation.
- Quality of Earnings Signals:
- Accruals Anomaly: High Net Income accompanied by declining Operating Cash Flow indicates aggressive revenue recognition.
- Stock-Based Compensation Dilution: Treat SBC as a real cash expense; add back dilution to share counts.
- Goodwill Impairments: Historical track record of M&A write-downs signals poor capital allocation.
2. Competitive Moat Assessment (Porter & Helmer Frameworks)
Evaluate structural competitive barriers:
- Network Effects: Value increases quadratically with user additions (Metcalfe's Law).
- Switching Costs: Cost to migrate to an alternative exceeds the expected savings (mission-critical enterprise software).
- Scale Economies: Declining marginal cost curve creating an insurmountable pricing advantage.
- Counter-Positioning: Incumbents cannot copy the new business model without cannibalizing their core revenue stream.
3. Financial Ratio & DuPont ROE Decomposition
Deconstruct Return on Equity (ROE) into operational efficiency, asset productivity, and leverage:
$$\text{ROE} = \left( \frac{\text{Net Income}}{\text{Revenue}} \right) \times \left( \frac{\text{Revenue}}{\text{Total Assets}} \right) \times \left( \frac{\text{Total Assets}}{\text{Shareholders' Equity}} \right)$$
- Net Profit Margin: Operating discipline and pricing power.
- Asset Turnover: Capital efficiency.
- Equity Multiplier: Degree of financial leverage.
4. Valuation Multiples & Margin of Safety
| Valuation Metric |
Formula |
Best Used For |
Warning Threshold |
| EV / NTM EBITDA |
$\frac{\text{Enterprise Value}}{\text{Next 12M Projected EBITDA}}$ |
Capital-intensive, profitable businesses |
Multiple > 2x peer historical median |
| EV / NTM Sales |
$\frac{\text{Enterprise Value}}{\text{Next 12M Projected Revenue}}$ |
High-growth, pre-profit SaaS |
Multiple > 15x without >40% growth |
| Free Cash Flow Yield |
$\frac{\text{FCF per Share}}{\text{Market Share Price}}$ |
Mature, cash-generating companies |
Yield < Risk-free 10-Yr Treasury rate |
| P/E to Growth (PEG) |
$\frac{\text{P/E Ratio}}{\text{Projected EPS Growth Rate}}$ |
Growth at a reasonable price (GARP) |
PEG > 2.0x |
Critical Rules
- Never value a growth company on gross revenue alone without accounting for stock-based compensation dilution.
- Always adjust EBITDA for capitalized software development costs and recurring maintenance CapEx.
- Every investment recommendation must state the specific falsification criteria: what verifiable milestone or metric degradation would invalidate the thesis.
Verification Checklist
Anti-Patterns
- NEVER rely on management-adjusted EBITDA figures that exclude regular, recurring cash expenses.
- NEVER initiate an investment position without an explicit target entry valuation incorporating a margin of safety.
- NEVER confuse high revenue growth with competitive moat; evaluate customer churn and pricing power.
1---2name: investment-research3description: Run market analysis, due diligence, valuation and portfolio review across asset classes. Use when evaluating public equities, earnings calls, or 10-K filings.4---56# Investment Research78Investment research requires rigorous fundamental analysis, accounting forensics, competitive moat assessment, and valuation modeling. Analyzing public equities, corporate filings, or private venture opportunities demands deconstructing SEC filings (10-K, 10-Q), evaluating management capital allocation track records, and modeling investment returns with explicit margin-of-safety parameters.910## 1. SEC Filing Deconstruction & Forensic Accounting1112Inspect audited financial statements for earnings quality:13- **Form 10-K (Annual) & Form 10-Q (Quarterly)**:14 - *Item 1 (Business)*: Moat analysis, customer concentration risks, supplier dependencies.15 - *Item 7 (Management's Discussion & Analysis - MD&A)*: Organic growth vs acquisition growth, pricing power, headwinds.16 - *Item 8 (Financial Statements & Notes)*: Revenue recognition policies, off-balance-sheet commitments, stock-based compensation (SBC), pending litigation.17- **Quality of Earnings Signals**:18 - *Accruals Anomaly*: High Net Income accompanied by declining Operating Cash Flow indicates aggressive revenue recognition.19 - *Stock-Based Compensation Dilution*: Treat SBC as a real cash expense; add back dilution to share counts.20 - *Goodwill Impairments*: Historical track record of M&A write-downs signals poor capital allocation.2122## 2. Competitive Moat Assessment (Porter & Helmer Frameworks)23Evaluate structural competitive barriers:24- **Network Effects**: Value increases quadratically with user additions (Metcalfe's Law).25- **Switching Costs**: Cost to migrate to an alternative exceeds the expected savings (mission-critical enterprise software).26- **Scale Economies**: Declining marginal cost curve creating an insurmountable pricing advantage.27- **Counter-Positioning**: Incumbents cannot copy the new business model without cannibalizing their core revenue stream.2829## 3. Financial Ratio & DuPont ROE Decomposition30Deconstruct Return on Equity (ROE) into operational efficiency, asset productivity, and leverage:31$$\text{ROE} = \left( \frac{\text{Net Income}}{\text{Revenue}} \right) \times \left( \frac{\text{Revenue}}{\text{Total Assets}} \right) \times \left( \frac{\text{Total Assets}}{\text{Shareholders' Equity}} \right)$$32- **Net Profit Margin**: Operating discipline and pricing power.33- **Asset Turnover**: Capital efficiency.34- **Equity Multiplier**: Degree of financial leverage.3536## 4. Valuation Multiples & Margin of Safety3738| Valuation Metric | Formula | Best Used For | Warning Threshold |39|---|---|---|---|40| **EV / NTM EBITDA** | $\frac{\text{Enterprise Value}}{\text{Next 12M Projected EBITDA}}$ | Capital-intensive, profitable businesses | Multiple > 2x peer historical median |41| **EV / NTM Sales** | $\frac{\text{Enterprise Value}}{\text{Next 12M Projected Revenue}}$ | High-growth, pre-profit SaaS | Multiple > 15x without >40% growth |42| **Free Cash Flow Yield** | $\frac{\text{FCF per Share}}{\text{Market Share Price}}$ | Mature, cash-generating companies | Yield < Risk-free 10-Yr Treasury rate |43| **P/E to Growth (PEG)** | $\frac{\text{P/E Ratio}}{\text{Projected EPS Growth Rate}}$ | Growth at a reasonable price (GARP) | PEG > 2.0x |4445## Critical Rules461. Never value a growth company on gross revenue alone without accounting for stock-based compensation dilution.472. Always adjust EBITDA for capitalized software development costs and recurring maintenance CapEx.483. Every investment recommendation must state the specific falsification criteria: what verifiable milestone or metric degradation would invalidate the thesis.4950## Verification Checklist51- [ ] 10-K financial statement notes reviewed for contingent liabilities and revenue recognition rules.52- [ ] Operating cash flow reconciled against net income to identify non-cash earnings inflation.53- [ ] Historical dilution modeled including outstanding stock option pools and RSUs.54- [ ] Valuation checked across multiple methodologies (DCF, historical multiples, sum-of-the-parts).55- [ ] Falsification criteria and downside bear-case scenario documented.5657## Anti-Patterns58- NEVER rely on management-adjusted EBITDA figures that exclude regular, recurring cash expenses.59- NEVER initiate an investment position without an explicit target entry valuation incorporating a margin of safety.60- NEVER confuse high revenue growth with competitive moat; evaluate customer churn and pricing power.